HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase priceNEW YORK...
Vaccine
Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai
TOKYO, Feb. 2, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY...
NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres
SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
IO Biotech Provides Corporate Update
Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:...
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million in upfront and...
ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
MELBOURNE, Australia, Jan. 29, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to...
Interim Results for the six months ended 31 October 2025
OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies...
Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026
2025: strong sales and EPS growth.Continued profitable growth expected in 2026 Paris, January 29, 2026 Q4 sales growth of 13.3%...
Ember LifeSciences to present on scaling reusable cold chains at Manifest Vegas 2026
Cold chain technology company to address reuse and visibility challenges; innovative products showcased at Exhibit Booth 1882LOS ANGELES, Jan. 28,...
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the...
Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site
BOSTON and STOCKHOLM, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mabtech, a global life science tools company specializing in advanced immunoassays,...
In HelloNation, Healthcare Expert Kim McKenna of Campbellsville, KY Discusses First Primary Care and Pediatric Visits
CAMPBELLSVILLE, Ky., Jan. 26, 2026 /PRNewswire/ -- What can families expect during their first primary care or pediatric visit? A HelloNation...
Voisin Consulting to Advance Pharmacovigilance Capabilities with Oracle
Oracle's leading safety platform will help Voisin enhance compliance, mitigate risk, and expand global service offerings for its pharmaceutical clientsAUSTIN,...
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a...
Genyro Signs Exclusive License for “Sidewinder,” a Breakthrough DNA Construction Technology Featured in Nature
A major technological advance in DNA writing enables researchers to construct and create in the language of biology The Genyro...
Invention of DNA “Page Numbers” Opens Up Vast Possibilities for the Bioeconomy
A major technological advance in DNA writing enables researchers to construct and create in the language of biologyPASADENA, Calif., Jan....
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision...
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The...
Telangana (India) Sets Global Ambition with Next-Gen Life Sciences Policy 2026-30
Positioning Telangana among the world's top five life sciences clusters by 2030Targets USD 25 billion in investments Shifts focus from...
ProgenyHealth Releases 2026 Maternal & Infant Health Trends Report
Report identifies 5 emerging trends within maternal and infant health and what they reveal about the state of the industry now...